Cargando…
Fatal COVID-19 in an MS patient on natalizumab: A case report
We report a fatal case of COVID-19 in a 51-year-old African American woman with multiple sclerosis on natalizumab. She had multiple risk factors for severe COVID-19 disease including race, obesity, hypertension, and elevated inflammatory markers, but the contribution of natalizumab to her poor outco...
Autores principales: | Rimmer, Kathryn, Farber, Rebecca, Thakur, Kiran, Braverman, Genna, Podolsky, Dina, Sutherland, Lauren, Migliore, Christopher, Ryu, Yun Kyoung, Levin, Seth, De Jager, Philip L, Vargas, Wendy, Levine, Libby, Riley, Claire S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425275/ https://www.ncbi.nlm.nih.gov/pubmed/32850133 http://dx.doi.org/10.1177/2055217320942931 |
Ejemplares similares
-
Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020) -
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017) -
Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015) -
Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021) -
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)